These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1083 related items for PubMed ID: 18223285

  • 1. ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission.
    Peyvandi F, Lavoretano S, Palla R, Feys HB, Vanhoorelbeke K, Battaglioli T, Valsecchi C, Canciani MT, Fabris F, Zver S, Réti M, Mikovic D, Karimi M, Giuffrida G, Laurenti L, Mannucci PM.
    Haematologica; 2008 Feb; 93(2):232-9. PubMed ID: 18223285
    [Abstract] [Full Text] [Related]

  • 2. Child-onset and adolescent-onset acquired thrombotic thrombocytopenic purpura with severe ADAMTS13 deficiency: a cohort study of the French national registry for thrombotic microangiopathy.
    Joly BS, Stepanian A, Leblanc T, Hajage D, Chambost H, Harambat J, Fouyssac F, Guigonis V, Leverger G, Ulinski T, Kwon T, Loirat C, Coppo P, Veyradier A, French Reference Center for Thrombotic Microangiopathies.
    Lancet Haematol; 2016 Nov; 3(11):e537-e546. PubMed ID: 27720178
    [Abstract] [Full Text] [Related]

  • 3. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura.
    Tsai HM, Lian EC.
    N Engl J Med; 1998 Nov 26; 339(22):1585-94. PubMed ID: 9828246
    [Abstract] [Full Text] [Related]

  • 4. Acquired thrombotic thrombocytopenic purpura: ADAMTS13 activity, anti-ADAMTS13 autoantibodies and risk of recurrent disease.
    Lämmle B, Kremer Hovinga JA, George JN.
    Haematologica; 2008 Feb 26; 93(2):172-7. PubMed ID: 18245649
    [No Abstract] [Full Text] [Related]

  • 5. Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies.
    Bresin E, Gastoldi S, Daina E, Belotti D, Pogliani E, Perseghin P, Scalzulli PR, Paolini R, Marcenò R, Remuzzi G, Galbusera M.
    Thromb Haemost; 2009 Feb 26; 101(2):233-8. PubMed ID: 19190804
    [Abstract] [Full Text] [Related]

  • 6. Pathogenicity of Anti-ADAMTS13 Autoantibodies in Acquired Thrombotic Thrombocytopenic Purpura.
    Thomas MR, de Groot R, Scully MA, Crawley JT.
    EBioMedicine; 2015 Aug 26; 2(8):942-52. PubMed ID: 26425702
    [Abstract] [Full Text] [Related]

  • 7. ADAMTS13-specific circulating immune complexes as potential predictors of relapse in patients with acquired thrombotic thrombocytopenic purpura.
    Mancini I, Ferrari B, Valsecchi C, Pontiggia S, Fornili M, Biganzoli E, Peyvandi F, Italian Group of TTP Investigators.
    Eur J Intern Med; 2017 Apr 26; 39():79-83. PubMed ID: 27887777
    [Abstract] [Full Text] [Related]

  • 8. Potential for Recombinant ADAMTS13 as an Effective Therapy for Acquired Thrombotic Thrombocytopenic Purpura.
    Tersteeg C, Schiviz A, De Meyer SF, Plaimauer B, Scheiflinger F, Rottensteiner H, Vanhoorelbeke K.
    Arterioscler Thromb Vasc Biol; 2015 Nov 26; 35(11):2336-42. PubMed ID: 26338302
    [Abstract] [Full Text] [Related]

  • 9. Prognostic value of inhibitory anti-ADAMTS13 antibodies in adult-acquired thrombotic thrombocytopenic purpura.
    Coppo P, Wolf M, Veyradier A, Bussel A, Malot S, Millot GA, Daubin C, Bordessoule D, Pène F, Mira JP, Heshmati F, Maury E, Guidet B, Boulanger E, Galicier L, Parquet N, Vernant JP, Rondeau E, Azoulay E, Schlemmer B, Réseau d'Etude des Microangiopathies Thrombotiques de l'Adulte.
    Br J Haematol; 2006 Jan 26; 132(1):66-74. PubMed ID: 16371021
    [Abstract] [Full Text] [Related]

  • 10. The clinical utility of ADAMTS13 activity, antigen and autoantibody assays in thrombotic thrombocytopenic purpura.
    Starke R, Machin S, Scully M, Purdy G, Mackie I.
    Br J Haematol; 2007 Feb 26; 136(4):649-55. PubMed ID: 17367414
    [Abstract] [Full Text] [Related]

  • 11. [Thrombotic Thrombocytopenic Purpura --Pathophysiology and Assays of ADAMTS13 Activity].
    Kato S, Fujimura Y.
    Rinsho Byori; 2015 Oct 26; 63(10):1228-36. PubMed ID: 26897861
    [Abstract] [Full Text] [Related]

  • 12. Persistence of circulating ADAMTS13-specific immune complexes in patients with acquired thrombotic thrombocytopenic purpura.
    Ferrari S, Palavra K, Gruber B, Kremer Hovinga JA, Knöbl P, Caron C, Cromwell C, Aledort L, Plaimauer B, Turecek PL, Rottensteiner H, Scheiflinger F.
    Haematologica; 2014 Apr 26; 99(4):779-87. PubMed ID: 24241492
    [Abstract] [Full Text] [Related]

  • 13. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.
    Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, Krause M, Scharrer I, Aumann V, Mittler U, Solenthaler M, Lämmle B.
    N Engl J Med; 1998 Nov 26; 339(22):1578-84. PubMed ID: 9828245
    [Abstract] [Full Text] [Related]

  • 14. Reduced ADAMTS13 activity is associated with thrombotic risk in systemic lupus erythematosus.
    Martin-Rodriguez S, Reverter JC, Tàssies D, Espinosa G, Heras M, Pino M, Escolar G, Diaz-Ricart M.
    Lupus; 2015 Oct 26; 24(11):1143-9. PubMed ID: 25824235
    [Abstract] [Full Text] [Related]

  • 15. ADAMTS-13 activity and autoantibodies classes and subclasses as prognostic predictors in acquired thrombotic thrombocytopenic purpura.
    Bettoni G, Palla R, Valsecchi C, Consonni D, Lotta LA, Trisolini SM, Mancini I, Musallam KM, Rosendaal FR, Peyvandi F.
    J Thromb Haemost; 2012 Aug 26; 10(8):1556-65. PubMed ID: 22672482
    [Abstract] [Full Text] [Related]

  • 16. Epitope analysis of autoantibodies to ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura.
    Yamaguchi Y, Moriki T, Igari A, Nakagawa T, Wada H, Matsumoto M, Fujimura Y, Murata M.
    Thromb Res; 2011 Aug 26; 128(2):169-73. PubMed ID: 21496883
    [Abstract] [Full Text] [Related]

  • 17. Paradigm shift of childhood thrombotic thrombocytopenic purpura with severe ADAMTS13 deficiency.
    Yagi H, Matsumoto M, Fujimura Y.
    Presse Med; 2012 Mar 26; 41(3 Pt 2):e137-55. PubMed ID: 22264931
    [Abstract] [Full Text] [Related]

  • 18. Measurement and prevalence of circulating ADAMTS13-specific immune complexes in autoimmune thrombotic thrombocytopenic purpura.
    Lotta LA, Valsecchi C, Pontiggia S, Mancini I, Cannavò A, Artoni A, Mikovic D, Meloni G, Peyvandi F.
    J Thromb Haemost; 2014 Mar 26; 12(3):329-36. PubMed ID: 24354764
    [Abstract] [Full Text] [Related]

  • 19. Link between von Willebrand factor multimers, relapses and coronary microcirculation in patients with thrombotic thrombocytopenic purpura in remission.
    Di Pasquale I, Budde U, Tona F, Bertomoro A, Lombardi AM, Famoso G, Bertozzi I, Dittmer R, Schneppenheim S, Fabris F.
    Thromb Res; 2019 Jan 26; 173():42-47. PubMed ID: 30471507
    [Abstract] [Full Text] [Related]

  • 20. [A study on the significance of plasma thrombospondin1 in thrombotic thrombocytopenic purpura and the relationship between thrombospondin1 and von Willebrand factor cleaving protease (ADAMTS13)].
    Liu F, Lu GY, Dong NZ, Bai X, Su J, Ruan CG.
    Zhonghua Yi Xue Za Zhi; 2005 Nov 30; 85(45):3190-3. PubMed ID: 16405838
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 55.